United Therapeutics UNITED Bond
UTH Stock | EUR 338.80 9.10 2.62% |
United Therapeutics has over 800 Million in debt which may indicate that it relies heavily on debt financing. . United Therapeutics' financial risk is the risk to United Therapeutics stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
United Therapeutics' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. United Therapeutics' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps United Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect United Therapeutics' stakeholders.
For most companies, including United Therapeutics, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for United Therapeutics, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, United Therapeutics' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
United |
Given the importance of United Therapeutics' capital structure, the first step in the capital decision process is for the management of United Therapeutics to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of United Therapeutics to issue bonds at a reasonable cost.
Popular Name | United Therapeutics UNITED TECHNOLOGIES P |
Equity ISIN Code | US91307C1027 |
Bond Issue ISIN Code | US913017CP20 |
United Therapeutics Outstanding Bond Obligations
UNITED TECHNOLOGIES P | US913017CR85 | Details | |
UNITED TECHNOLOGIES P | US913017CP20 | Details | |
UNITED TECHNOLOGIES P | US913017CW70 | Details | |
UNITED TECHNOLOGIES P | US913017CY37 | Details | |
UNITED TECHNOLOGIES P | US913017CX53 | Details | |
Dana 575 percent | US235822AB96 | Details | |
UNITED TECHNOLOGIES P | US913017DD80 | Details | |
Volcan Compania Minera | USP98047AC08 | Details | |
UNITED TECHNOLOGIES P | US913017BP39 | Details | |
UNITED TECHNOLOGIES P | US913017BT50 | Details | |
UNITED TECHNOLOGIES P | US913017BS77 | Details | |
UNITED TECHNOLOGIES P | US913017CA50 | Details | |
UNITED TECHNOLOGIES P | US913017CJ69 | Details | |
UNITED TECHNOLOGIES P | US913017CH04 | Details | |
HSBC Holdings PLC | US404280DR76 | Details | |
MPLX LP 4125 | US55336VAK61 | Details | |
International Game Technology | US460599AD57 | Details | |
Morgan Stanley 3591 | US61744YAK47 | Details | |
MGM Resorts International | US552953CD18 | Details | |
Valero Energy Partners | US91914JAA07 | Details | |
UNITED TECHNOLOGIES P | US913017AT69 | Details | |
UNITED TECHNOLOGIES P | US913017BA69 | Details | |
UNITED TECHNOLOGIES P | US913017BK42 | Details | |
UNITED TECHNOLOGIES P | US913017BJ78 | Details | |
AerCap Global Aviation | US00773HAA59 | Details |
Understaning United Therapeutics Use of Financial Leverage
United Therapeutics' financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures United Therapeutics' total debt position, including all outstanding debt obligations, and compares it with United Therapeutics' equity. Financial leverage can amplify the potential profits to United Therapeutics' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if United Therapeutics is unable to cover its debt costs.
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland. UTD THERAP operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 860 people. Please read more on our technical analysis page.
Currently Active Assets on Macroaxis
BTC | Bitcoin | |
TRX | TRON | |
BNB | Binance Coin | |
ADA | Cardano | |
XRP | XRP |
Additional Information and Resources on Investing in United Stock
When determining whether United Therapeutics is a strong investment it is important to analyze United Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact United Therapeutics' future performance. For an informed investment choice regarding United Stock, refer to the following important reports:Check out the analysis of United Therapeutics Fundamentals Over Time. For more detail on how to invest in United Stock please use our How to Invest in United Therapeutics guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.